Thanks, and good morning everyone. As Bilal mention, this was a strong quarter from a net investment income perspective and our NAV was stable. We continue to see the benefits of our increased scale and asset-based. Starting with the income statement, we derived approximately $12.3 million in total investment income in the quarter, a $300,000 decrease over the fourth quarter. Total expenses of $7.5 million increased $200,000 compared to the prior quarter. This increase was driven by higher interest expense due to a full quarter related to our October 2018 bond offering and higher outstanding line of credit balances used to fund additional investment activity, resulting net investment income per share of $0.36 compared to $0.40 in the prior quarter. The decrease was driven by lower fee income and fewer accelerations of original issuance discount quarter, partly offset by a full quarter of income related to the deployment of last October's bond proceeds. It is worth noting that recurring earnings, earnings excluding fee income and original issue discount accelerations are up. Turning to the balance sheet. We had approximately $15 million of un-invested cash at the end of the quarter. $13 million of that cash was in our SBIC. We had considerable deployment of cash during the quarter at the SBIC. To allow for continued growth and improved earnings, we recently renegotiated our $50 million Pacwest line of credit and were successful at upsizing the facility to $100 million. We also achieved more favorable pricing, which decreased by 50 basis points. In addition, we were able to negotiate more flexible leverage covenants to align the financing with the change to 150% statutory asset coverage. As a result of this facility upsize, we currently have approximately $61.5 million in undrawn availability on our line of credit. Our debt to equity ratio at the end of the quarter was about 1.64 times, including our SBIC debt. As you know, this is well below our regulatory leverage requirements as the SBIC debt does not count towards the leverage test. We would be comfortable increasing our leverage further in order to invest in senior secured loans of larger companies. Our net asset value is pretty stable at the end of the quarter at $13.04 per share compared to $13.10 in the prior quarter. As far as our investments, at the end of the quarter, we had investments in 51 companies totaling $438 million on a fair value basis. As a percentage of costs, our investments were approximately 77% senior secured loans, 12% subordinated debt, 3% structured finance notes and 8% equity, approximately two thirds of which is in preferred equity securities. Our portfolio remains diversified with an average investment in this portfolio company of $8.6 million or 2% of the portfolio's total fair value. At fair value, we currently have 0.2% of the portfolio on non-accrual the same as last quarter. Overall, weighted average yield to costs on our performing debt investments was 11.8% at March 31st. This compares to our weighted average cost on our borrowings of just under 5% at quarter's end. We deployed approximately $63.6 million in the first quarter across nine investments. This consisted of $12.7 million to several existing portfolio companies, and we also invested $50.9 million in five new companies. The new names consisted mostly of floating rate and senior secured loans along with some structured finance notes. The weighted average yield to cost of the new investments during the quarter was 13.4%. One of the new investments I would like to highlight is our investment in Chemres, which we closed during the first quarter. We made $15 million investment in a floating rate senior secured loan facility and $2 million common equity investment to help finance the acquisition of the company. Chemres has been in business for nearly 25 years, and is a formulator and manufacture and supply chain manager of high performance polymers and plastics. The OFS team directly sourced and underwrote the deal. The five year facility has a full covenant package and we secured board observation rights. The last dollar of debt leverage at closing was just under 4 times and the pricing stands today at about 11%. We believe this is a strong investment process. Chemres count several fortune 500 companies as its customers and the majority of its top customers have been customers for more than 10 years. The company serves several end markets, including medical, wire installation, chemicals and consumer packaging, among others. Chemres has economically resilient characteristics and saw just a minimal decline in gross profit during the last downturn. The management team has been together for eight years and we will continue to have significant ownership in the company. As such, we are happy to have Chemres among a group of portfolio investments. With that, I will turn the call back over to Bilal.